Richard C. Mulligan | |
|---|---|
| Alma mater | Massachusetts Institute of Technology, Stanford University |
| Known for | Gene Therapy |
| Scientific career | |
| Fields | Gene Therapy |
| Institutions | Massachusetts Institute of Technology, Harvard Medical School, Sana Biotechnology |
| Doctoral advisor | Paul Berg |
| Other academic advisors | Alexander Rich, David Baltimore, Phillip Allen Sharp |
| Notable students | James Wilson (scientist), Constance Cepko, David Sanders (biologist), Roger D. Cone |
Richard C. Mulligan (born 1954) is an American scientist who is the Mallinckrodt Professor of Genetics at Harvard Medical School,[1][2][3] the Director of the Harvard Gene Therapy Initiative and a visiting scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.[4] He is also the head of SanaX at Sana Biotechnology.[5]
- ^ "Richard C. Mulligan, Ph.D. | HMS Department of Genetics". genetics.med.harvard.edu. May 2016. Retrieved 2016-06-21.
- ^ "Harvard BBS PHD Program".
- ^ "Richard C. Mulligan, Ph.D. - DF/HCC". dfhcc.harvard.edu. Archived from the original on 2015-05-31. Retrieved 2016-06-21.
- ^ "Richard C. Mulligan". people.forbes.com. Archived from the original on August 4, 2011. Retrieved 2016-06-21.
- ^ "Richard Mulligan, Ph.D., Head of SanaX". Retrieved Dec 24, 2024.